Compare Regeneron Pharmaceuticals Inc (REGN) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Teucrium Wheat Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Teucrium Wheat Fund trades at $25.99. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Teucrium Wheat Fund pays none, and Teucrium Wheat Fund is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | WEAT | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $812.27 | $25.49 |
52-Week Low | $545.46 | $19.88 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
WEAT, the Teucrium Wheat Fund ETF, trades at $24.99, down 1.03% on the day, yet maintains a strong bullish technical trend with moving averages signaling buy. The fund has surged approximately 25% year-to-date, driven by wheat price increases and supply concerns highlighted by recent USDA production cuts. However, oscillators indicate potential short-term overbought conditions with RSI readings above 80.
The outlook for WEAT remains positive given fundamental agricultural supply constraints and inflation trends, but faces risks from potential price corrections after rapid gains and broader commodity market volatility. Investment appeal hinges on continued wheat market strength, though current technical indicators suggest caution for near-term entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
